NeuroSense Therapeutics Ltd., a clinical-stage drug development company and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced today a collaboration to...
NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, announced it has received approval from the Italian Medicines Agency (AIFA) to commence...
The U.S. Food and Drug Administration approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...
